<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432315</url>
  </required_header>
  <id_info>
    <org_study_id>TAX_AT1_203</org_study_id>
    <nct_id>NCT00432315</nct_id>
  </id_info>
  <brief_title>Docetaxel in Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Multicenter Phase II Study Evaluating Docetaxel and CDDP as Induction Regimen Prior to Surgery or Radiochemotherapy With Docetaxel, Followed by Adjuvant Docetaxel Therapy in Chemonaive Patients With NSCLC Stage II, IIIa and IIIb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

      • To assess the response rate to induction therapy with docetaxel/CDDP.

      Secondary objectives:

      To assess

        -  Resectability after induction therapy

        -  Time to progression

        -  Overall survival

        -  Safety profile

        -  Quality of Life
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the response rate to induction therapy with docetaxel in combination with CDDP</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resectability after induction therapy</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>every 3 months until tumour progression and thereafter every 6 months until death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resectable NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unresectable NSCSC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + CDDP</intervention_name>
    <description>3 cycles chemotherapy : docetaxel + CDDP
Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)
3 cycles adjuvant chemotherapy docetaxel</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel + CDDP</intervention_name>
    <description>3 cycles chemotherapy: docetaxel + CDDP
Radiochemotherapy
3 cycles adjuvant chemotherapy docetaxel</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histology and staging of the disease

               -  Histologically or cytologically confirmed NSCLC; histology may include: large
                  cell, squamous cell or adenocarcinoma but no SCLC

               -  Resectable or unresectable NSCLC stage II (T1-2 N1, T3 N0) or stage IIIa (T1-2 N2
                  or T3 N1-2) or stage IIIb (T1-3 N3 or T4 N0-3)

               -  Measurable disease (bidimensionally or unidimensionally according to WHO
                  criteria)

          2. General conditions

               -  Karnofsky Status &gt; 70, if age &gt; 70 years → PS &gt; 70

               -  Adequate hematological function (Hb &gt; 10 g/dl, ANC &gt; 2.0 x 109/L, platelets &gt; 100
                  x 109/L)

               -  Adequate renal and hepatic functions: total bilirubin &lt; 1 x upper normal limit
                  (UNL), serum creatinine &lt; 1 x UNL, in case of limit value the creatinine
                  clearance should be &gt; 60 ml/min, ASAT and ALAT &lt; 2.5 x UNL, alkaline phosphatase
                  &lt; 5 x UNL.

        Exclusion Criteria:

          1. Diagnosis

               -  Evidence of brain metastases or other distant metastasis equivalent to stage IV
                  disease

               -  History of prior malignancies, except for curatively treated non-melanoma skin
                  cancer or in situ carcinoma of the cervix or other curatively treated cancer with
                  no evidence of disease for at least five years

               -  Other serious concomitant illness or medical condition:

                    -  Congestive heart failure or angina pectoris, except if medically controlled,
                       history of myocardial infarction within 1 year from study entry,
                       uncontrolled hypertension or arrhythmia

                    -  History of significant neurologic or psychiatric disorders, including
                       dementia or seizure

                    -  Active infection requiring i.v. Antibiotics

                    -  Active ulcer, unstable diabetes mellitus or other contraindications to
                       corticotherapy

               -  Hepatic function abnormality: ASAT and/or ALAT &gt; 1.5 x UNL associated with
                  alkaline phosphatase &gt; 2.5 x UNL

               -  Current peripheral neuropathy WHO grade &gt; 2

          2. Prior or concurrent therapy

               -  Prior chemotherapy or immunotherapy for NSCLC, including neoadjuvant or adjuvant
                  treatment

               -  Prior surgery or radiotherapy for NSCLC

               -  Concurrent treatment with other experimental drugs, unapproved medical procedures
                  or other anticancer therapy

          3. General conditions

               -  Pregnant or lactating patients

               -  Patients (M/F) with reproductive potential not implementing adequate
                  contraceptive measurements

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Edlmayer, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2007</study_first_submitted>
  <study_first_submitted_qc>February 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2007</study_first_posted>
  <last_update_submitted>September 13, 2010</last_update_submitted>
  <last_update_submitted_qc>September 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

